DOCSLIB.ORG

Tesi Finale Lodicoalessia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tesi Finale Lodicoalessia UNIVERSITÀ DEGLI STUDI DI MILANO SCUOLA DI DOTTORATO IN MEDICINA MOLECOLARE CICLO XXVI Anno Accademico 2012/2013 TESI DI DOTTORATO DI RICERCA MED/36 Multimodal molecular imaging for HIF-1α non-invasive assessment in a murine glioma model Dottorando : Alessia LO DICO Matricola N° R09155 TUTORE: Dott.ssa Luisa OTTOBRINI DIRETTORE DEL DOTTORATO: Chiar.mo Prof. Mario CLERICI INDEX INDEX ......................................................................................................................................... I LIST OF ABBREVIATIONS ........................................................................................................ V LIST OF FIGURES .................................................................................................................. VIII SOMMARIO ............................................................................................................................. XII ABSTRACT ............................................................................................................................ XIV INTRODUCTION ........................................................................................................................ 1 1. GLIOMA ................................................................................................................................. 2 1.1 GLIOBLASTOMA ............................................................................................................... 4 1.1.1 CELLULAR COMPOSITION OF GBM ...................................................................... 6 1.1.2 GENETIC OF GBM ................................................................................................... 7 2. HYPOXIA ............................................................................................................................... 9 2.1 HIF-1α .............................................................................................................................. 11 3. HYPOXIA IN GLIOMA DISEASE .......................................................................................... 13 3.1 GLIOMA MODELS ........................................................................................................... 14 4. EFFECT OF DRUG ACTIVITY ON HIF-1α MODULATION ................................................... 16 4.1 HYPOXIA MIMETIC: DFX ................................................................................................ 16 4.2 PI3K PATHWAY INHIBITORS: LY294002 AND BEZ-235 ................................................ 17 4.3 MEK PATHWAY MODULATORS: TRAMETINIB AND PD98059 ..................................... 18 4.4 HIF-1Α MODULATORS: FM19G11 AND DMOG .............................................................. 19 4.5 TEMOZOLOMIDE ............................................................................................................ 19 5. IN VIVO IMAGING ................................................................................................................ 21 5.1 OPTICAL IMAGING ......................................................................................................... 25 5.1.1 BIOLUMINESCENCE ............................................................................................. 27 5.1.2 FLUORESCENCE .................................................................................................. 29 I 5.2 NUCLEAR IMAGING ........................................................................................................ 31 5.3 MAGNETIC RESONANCE IMAGING .............................................................................. 35 6. HYPOXIA AND HIF-1α ACTIVITY IMAGING ........................................................................ 36 AIM OF THE STUDY ................................................................................................................ 42 MATERIALS AND METHODS .................................................................................................. 44 1. IN VITRO EXPERIMENTS .................................................................................................. 45 1.1 CELLS LINES AND REAGENTS...................................................................................... 45 1.2 U251-HRE INFECTION .................................................................................................... 45 1.3 DRUG PREPARATION FOR IN VITRO STUDIES ........................................................... 45 1.4 DFX MODULATION OF LUCIFERASE ACTIVITY ........................................................... 46 1.5 NUCLEAR HIF-1Α DETECTION BY IMMUNOCYTOCHEMISTRY ASSAY (ICC) ............ 46 1.6 NUCLEAR HIF-1Α DETECTION BY TRANSAM KIT ........................................................ 46 1.7 EFFECTS OF LY294002 AND FM19G11 ON LUCIFERASE ACTIVITY IN LIVING AND LYSATED CELLS .................................................................................................................. 47 1.8 EFFECTS OF BEZ235 AND TRAMETINIB TREATMENT ON LUCIFERASE ACTIVITY . 47 1.9 IN VITRO TMZ TREATMENT ........................................................................................... 47 1.10 MTT ASSAY ................................................................................................................... 48 2. IN VIVO EXPERIMENTS ...................................................................................................... 48 2.1 ANIMAL STUDIES ........................................................................................................... 48 2.2 IN VIVO IMAGING STUDY DESIGN ................................................................................ 49 2.3 BLI AND FLI STUDIES ..................................................................................................... 49 2.4 MRI ANALYSIS ................................................................................................................ 50 2.5 PET ANALYSIS ................................................................................................................ 50 2.6 IMMUNOHISTOCHEMISTRY (IHC) ................................................................................. 51 2.7 IN VIVO IMAGING AFTER TEMOZOLOMIDE TREATMENT ........................................... 51 2.8 STATISTICAL ANALYSIS ................................................................................................ 52 II RESULTS AND DISCUSSION ................................................................................................. 53 1. IN VITRO CHARACTERIZATION OF LUCIFERASE ACTIVITY IN RELATION TO .............. 54 HIF-1α MODULATION.............................................................................................................. 54 1.1 DFX MODULATION OF LUCIFERASE ACTIVITY ........................................................... 54 1.2 NUCLEAR DETECTION OF HIF-1α ................................................................................. 56 1.3 EFFECTS OF LY294002 AND FM19G11 ON LUCIFERASE ACTIVITY .......................... 58 1.4 IN VITRO EVALUATION OF HIF-1α REGULATION BY DIFFERENT DRUGS ................ 61 1.5 IN VITRO TMZ TREATMENT ........................................................................................... 66 2. IN VIVO STUDY OF LUCIFERASE ACTIVITY IN RELATION TO INTRATUMORAL HYPOXIA ............................................................................................................................... 69 2.1 BLI ANALYSIS ................................................................................................................ 69 2.2 FLI VALIDATION OF BLI RESULTS ................................................................................ 72 2.3. IN VIVO STUDY OF TUMOR FEATURES BY MRI AND NUCLEAR-BASED IMAGING (PET) ..................................................................................................................................... 73 3. EX VIVO VALIDATION ......................................................................................................... 77 3.1. MORPHOLOGICAL AND IMMUNOHISTOCHEMICAL ANALYSES ................................ 77 4. IN VIVO TEMOZOLOMIDE TREATMENT ............................................................................ 78 CONCLUSIONS ....................................................................................................................... 85 FUTURE PERSPECTIVE ......................................................................................................... 88 BIBLIOGRAPHY ....................................................................................................................... 90 SCIENTIFIC PRODUCTS ...................................................................................................... 105 GRANTS ................................................................................................................................ 106 III IV LIST OF ABBREVIATIONS [64 Cu]ATSM: Copper diacetyl-bis (N4-methylthiosemicarbazone) ATP: Adenosine TriPhosphate BBB: Blood Brain Barrier BL: Bioluminescence BMDC: Bone Marrow Derived Cells CAIX: Carbonic Anhydrase IX cCCD: Cooled Charge-Coupled Device Cdks: Cyclin-Dependent Kinases CK2: Casein Kinase 2 CNS: Central Nervous System CoCl2: Cobalt Chloride CT: Computerized Tomography D2R : Dopaminergic type 2 Receptor DCE-MRI: Dynamic Contrast-Enhanced Magnetic Resonance Imaging DFX: Deferoxamine DMOG: DiMethylOxalylGlycine DNA-PK: DNA-dependent Protein Kinase EGFR: Epidermal Growth Factor Receptor [18 F]FAZA: 18F-FluoroAzomycin Arabinoside
Load more

Recommended publications
  • WO 2013/134349 Al 12 September 2013 (12.09.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/134349 Al 12 September 2013 (12.09.2013) P O P C T (51) International Patent Classification: (74) Agents: CASSIDY, Timothy, A. et al; Dority & Man A61K 45/06 (2006.01) A61P 35/00 (2006.01) ning, P.A., P O Box 1449, Greenville, SC 29602-1449 A61K 9/50 (2006.01) A61K 47/48 (2006.01) (US). A61K 9/51 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US20 13/029294 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 6 March 2013 (06.03.2013) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (26) Publication Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (30) Priority Data: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, 61/607,036 6 March 2012 (06.03.2012) US TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, 13/784,930 5 March 2013 (05.03.2013) US ZM, ZW.
    [Show full text]
  • Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide KAVINDRA NATH 1, DAVID S
    ANTICANCER RESEARCH 37 : 3413-3421 (2017) doi:10.21873/anticanres.11708 Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide KAVINDRA NATH 1, DAVID S. NELSON 1, JEFFREY ROMAN 1, MARY E. PUTT 2, SEUNG-CHEOL LEE 1, DENNIS B. LEEPER 3 and JERRY D. GLICKSON 1 Departments of 1Radiology and 2Biostatistics & Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, U.S.A.; 3Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, U.S.A. Abstract. Background/Aim: Since temozolomide (TMZ) is stages. However, following recurrence with metastasis, the activated under alkaline conditions, we expected lonidamine prognosis is poor. Mutationally-activated BRAF is found in (LND) to have no effect or perhaps diminish its activity, but 40-60% of all melanomas with most common substitution of initial results suggest it may actually enhance either or both valine to glutamic acid at codon 600 (p. V600E) (3). Overall short- and long-term activity of TMZ in melanoma xenografts. survival is approaching two years using agents that target this Materials and Methods: Cohorts of 5 mice with subcutaneous mutation (4, 5). MEK, RAS and other signal transduction xenografts ~5 mm in diameter were treated with saline inhibitors, in combination with mutant BRAF inhibitors, have (control (CTRL)), LND only, TMZ only or LND followed by been used to deal with melanoma resistance to these agents TMZ at t=40 min (time required for maximal tumor (6). Treatment with anti-programmed death-1 (PD-1) acidification). Results: Mean tumor volume for LND+TMZ for checkpoint inhibitor immunotherapy currently produces the period between 6 and 26 days was reduced compared to durable response in about 25% of melanoma patients (7-10).
    [Show full text]
  • Activity of Mitozolomide (NSC 353451), a New Imidazotetrazine, Against Xenografts from Human Melanomas, Sarcomas, and Lung and Colon Carcinomas
    (CANCER RESEARCH 45, 1778-1786, April 1985] Activity of Mitozolomide (NSC 353451), a New Imidazotetrazine, against Xenografts from Human Melanomas, Sarcomas, and Lung and Colon Carcinomas Oy stein Fodstad, ' Steina r Aamdal,2 Alexander Pihl, and Michael R. Boyd Norsk Hydros Institute for Cancer Research, Montebello, Oslo 3, Norway [0. F., S. Aa., A. P.] and Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20205 [0. F., M. R. B.¡ ABSTRACT In this investigation, we first tested the anticancer activity of mitozolomide against cells from different xenografted cancers in The chemosensitivity of human tumor xenografts to mitozo- a HTCF assay in vitro. When a pronounced inhibition of colony lomide, 8-carbamoyl-3-{2-chloroethyl)imidazo[5-1 -d]-1,2,3,5-te- formation was observed, we next examined in the HTCF assay trazin-4(3H)-one, was studied in 3 different assay systems. In the efficiency of the drug on a panel of tumors for each histolog concentrations of 1 to 500 ¿/g/ml,mitozolomide completely inhib ical type. Since in vitro test systems have inherent limitations ited the colony-forming ability in soft agar of cell suspensions (23), we also measured the in vivo effect of mitozolomide on the from sarcomas, melanomas, lung and colon cancers, and a same tumors, using the 6-day subrenal capsule assay in immu- mammary carcinoma. When a panel of tumors of the different nocompetent mice (1-3), as well as s.c. growing tumors in histological types was tested for its sensitivity to mitozolomide athymic, nude mice (5-7, 10, 16, 18).
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • The Role of Receptor Tyrosine Kinases in Mediating Glioblastoma Resistance to Radiotherapy and Temozolomide
    The role of receptor tyrosine kinases in mediating glioblastoma resistance to radiotherapy and temozolomide Zammam Areeb ORCID: 0000-0003-1405-6139 Submitted to the University of Melbourne in total fulfilment of the requirements of the degree of Doctor of Philosophy January 2020 The Department of Surgery The Royal Melbourne Hospital The University of Melbourne ABSTRACT Glioblastoma is the most common and aggressive form of malignant glioma. Currently, despite treatment with surgery followed by radiotherapy and the chemotherapeutic agent temozolomide (TMZ), mean patient survival time is approximately 12 months and the 5-year survival rate is close to 0%. A key factor for the dismal prognosis is tumour recurrence post- treatment which is largely due to: 1) the infiltrative nature of glioblastoma rendering complete resection impossible and 2) glioblastoma cell resistance to radio-chemotherapy. In this thesis we aimed to investigate the cellular mechanisms of receptor tyrosine kinases in conferring resistance to therapy. We first performed a literature search and found that almost all studies that advocated for the utility of targeting RTKs in overcoming treatment resistance did not employ both therapeutic agents comprising standard therapy – radiotherapy and TMZ. We next generated an in vitro glioblastoma resistant model via short-term treatment with radiotherapy and TMZ and found that these cells had down-regulated RTK activity in addition to down-regulated protein and gene expression of the commonly altered and studied epidermal growth factor receptor (EGFR) and MET receptor. After generating an in vitro glioblastoma recurrent model via long-term treatment we demonstrated that the surviving sub-population of cells also displayed down-regulated EGFR and MET expression compared to treatment naïve cells.
    [Show full text]
  • Autophagy As a Potential Therapy for Malignant Glioma
    pharmaceuticals Review Autophagy as a Potential Therapy for Malignant Glioma Angel Escamilla-Ramírez 1 , Rosa A. Castillo-Rodríguez 2 , Sergio Zavala-Vega 3, Dolores Jimenez-Farfan 4 , Isabel Anaya-Rubio 1, Eduardo Briseño 5, Guadalupe Palencia 1, Patricia Guevara 1, Arturo Cruz-Salgado 1, Julio Sotelo 1 and Cristina Trejo-Solís 1,* 1 Departamento de Neuroinmunología, Instituto Nacional de Neurología y Neurocirugía, Ciudad de México 14269, Mexico; [email protected] (A.E.-R.); [email protected] (I.A.-R.); [email protected] (G.P.); [email protected] (P.G.); [email protected] (A.C.-S.); [email protected] (J.S.) 2 Laboratorio de Oncología Experimental, CONACYT-Instituto Nacional de Pediatría, Ciudad de México 04530, Mexico; [email protected] 3 Departamento de Patología, Instituto Nacional de Neurología y Neurocirugía, Ciudad de México 14269, Mexico; [email protected] 4 Laboratorio de Inmunología, División de Estudios de Posgrado e Investigación, Facultad de Odontología, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico; [email protected] 5 Clínica de Neurooncología, Instituto Nacional de Neurología y Neurocirugía, Ciudad de México 14269, Mexico; [email protected] * Correspondence: [email protected]; Tel.: +52-555-060-4040 Received: 5 June 2020; Accepted: 14 July 2020; Published: 19 July 2020 Abstract: Glioma is the most frequent and aggressive type of brain neoplasm, being anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM), its most malignant forms. The survival rate in patients with these neoplasms is 15 months after diagnosis, despite a diversity of treatments, including surgery, radiation, chemotherapy, and immunotherapy. The resistance of GBM to various therapies is due to a highly mutated genome; these genetic changes induce a de-regulation of several signaling pathways and result in higher cell proliferation rates, angiogenesis, invasion, and a marked resistance to apoptosis; this latter trait is a hallmark of highly invasive tumor cells, such as glioma cells.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
    biomedicines Review Temozolomide and Other Alkylating Agents in Glioblastoma Therapy 1, 1, 1, 2 3 Hannah Strobel y, Tim Baisch y, Rahel Fitzel y, Katharina Schilberg , Markus D. Siegelin , Georg Karpel-Massler 4, Klaus-Michael Debatin 1 and Mike-Andrew Westhoff 1,* 1 Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, D-89075 Ulm, Germany 2 Faculty of Medicine, Ulm University, D-89081 Ulm, Germany 3 Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA 4 Department of Neurosurgery, University Medical Center Ulm, D-89081 Ulm, Germany * Correspondence: andrew.westhoff@uniklinik-ulm.de These authors contributed equally to this work. y Received: 12 August 2019; Accepted: 2 September 2019; Published: 9 September 2019 Abstract: The alkylating agent temozolomide (TMZ) together with maximal safe bulk resection and focal radiotherapy comprises the standard treatment for glioblastoma (GB), a particularly aggressive and lethal primary brain tumor. GB affects 3.2 in 100,000 people who have an average survival time of around 14 months after presentation. Several key aspects make GB a difficult to treat disease, primarily including the high resistance of tumor cells to cell death-inducing substances or radiation and the combination of the highly invasive nature of the malignancy, i.e., treatment must affect the whole brain, and the protection from drugs of the tumor bulk—or at least of the invading cells—by the blood brain barrier (BBB). TMZ crosses the BBB, but—unlike classic chemotherapeutics—does not induce DNA damage or misalignment of segregating chromosomes directly. It has been described as a DNA alkylating agent, which leads to base mismatches that initiate futile DNA repair cycles; eventually, DNA strand breaks, which in turn induces cell death.
    [Show full text]
  • FIGURE 1 Human Subjects with Bispecific Anti-CD 123 X Anti-CD3 Antibodies
    ( (51) International Patent Classification: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, A61K 39/395 (2006.01) A61P 35/02 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. A61P 35/00 (2006.01) C07K 16/28 (2006.01) (84) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of regional protection available) . ARIPO (BW, GH, PCT/US20 19/035203 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (22) International Filing Date: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 03 June 2019 (03.06.2019) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (25) Filing Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, (26) Publication Language: English KM, ML, MR, NE, SN, TD, TG). (30) Priority Data: 62/679,25 1 0 1 June 2018 (01.06.2018) US Published: 62/713,439 0 1 August 2018 (01.08.2018) US — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (71) Applicant: XENCOR, INC. [US/US]; 111 West Lemon claims and to be republished in the event of receipt of Avenue, Monrovia, CA 91016 (US). amendments (Rule 48.2(h)) (72) Inventors: SAVILLE, Michael, Wayne; d o Xencor, Inc., — with sequence listing part of description (Rule 5.2(a)) I l l West Lemon Avenue, Monrovia, CA 91016 (US).
    [Show full text]
  • Making the Most of Rodent Tumour Systems in Cancer Drug Discovery
    British Journal of Cancer (1999) 79(11/12), 1633–1640 © 1999 Cancer Research Campaign Article no. bjoc.1998.0261 Review Making the most of rodent tumour systems in cancer drug discovery MC Bibby Clinical Oncology Unit, University of Bradford, Richmond Road, Bradford, West Yorkshire, BD7 1DP, UK It is clear that even after almost half a century of intensive effort to tors believed that the use of more appropriate, slower growing develop effective treatments for common solid cancers there is tumour models of solid cancers, and adoption of clinically relevant still some way to go before a major impact on survival of patients end-points, would improve the usefulness of preclinical studies, with these malignancies is achieved. Much of the paucity of particularly for agents with potential activity against the common success is blamed on the lack of appropriate models and there is a solid cancers. Corbett et al (1987) pointed out that most of the commonly held belief amongst cancer researchers that trans- agents that had entered the clinic at that time had poor, or no, plantable tumours in rodents are sensitive to drug therapy, are easy activity against the majority of transplantable solid tumours in to cure and therefore not predictive of responses in humans. It is mice but they also suggested that, as negative findings are rarely true that, in the past, when one considers the large number of reported, the casual reader of the drug discovery literature may compounds evaluated, murine tumour models have identified only have gained the inaccurate impression that transplantable tumours a limited number of clinically useful agents and not a single in mice are highly vulnerable to a large proportion of agents that cancer-specific drug has resulted from a murine tumour screen.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0200250 A1 Peng Et Al
    US 2014020O250A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0200250 A1 Peng et al. (43) Pub. Date: Jul. 17, 2014 (54) ANTI-CANCERAGENTS (60) Provisional application No. 61/503,957, filed on Jul. 1, 2011. (71) Applicant: UWM Research Foundation, Inc., Milwaukee, WI (US) Publication Classification (72) Inventors: Xiaohua Peng, Milwaukee, WI (US); (51) Int. Cl. Yunyan Kuang, Shanghai City (CN); C07D 207/50 (2006.01) Sheng Cao, Milwaukee, WI (US); A6II 45/06 (2006.01) Wenbing Chen, Milwaukee, WI (US); A613 L/478 (2006.01) Yibin Wang, Milwaukee, WI (US) (52) U.S. Cl. CPC .......... CO7D 207/50 (2013.O1): 46K 3/478 (73) Assignee: UWM Research Foundation, Inc., ( ); Milwaukee, WI (US (2013.01); A61K 45/06 (2013.01) ilwaukee, WI (US) USPC ......................... 514/397: 548/313.7; 435/375 (21)21) Appl. NoNo.: 14/136,0259 (57) ABSTRACT (22) Filed: Dec. 20, 2013 Described herein are compounds that may be selectively acti Related U.S. Application Data vated to produce active anti-cancer agents in tumor cells. Also disclosed are pharmaceutical compositions comprising the (62) Division of application No. 13/539,471, filed on Jul. 1, compounds, and methods of treating cancer using the com 2012, now Pat. No. 8,637,490. pounds. Patent Application Publication Jul. 17, 2014 Sheet 1 of 13 US 2014/0200250 A1 Compound 6 6 7 7 17a 17a 8 8 9 9 10 10 5 5 Ho - + - + - + - + - + - + - + DNA Cross-link <" ssDNA 1 2 3 4 5 6 7 8 9 O 11 12 13 14 FG. Patent Application Publication Jul.
    [Show full text]
  • Drug Metabolism Group
    Br. J. Cancer (1985), 52, 409-468 Twenty-Sixth Annual General Meeting of the British Association for Cancer Research* (in conjunction with the European Organization for Research and Treatment for Cancer -Pharmacokinetics and Metabolism Group and the Drug Metabolism Group) (Incorporating Symposia on 'Reactive intermediates in drug metabolism and carcinogenicity', 'New directions in the therapy of cancer', 'The early clinical trials of novel antitumour agents'; the 1985 Walter Hubert Lecture: and the West Midlands Oncology Association Guest Lecture) March 24-27, 1985. Held at Aston University, Birmingham, UK. Abstracts of invited paperst Symposium: aromatase, as potential therapeutic agents in the treatment of oestrogen-dependent tumours. Reactive intermediates in drug metabolism and carcinogenicity The role of reactive electrophiles in biological activity The generation and fate of free radicals in intact and toxicity cells S.D. Nelson S. Orrenius Department of Medicinal Chemistry BG-20, Department of Toxicology, Karolinska Institutet, University of Washington, Seattle, WA 98195 USA. S-104 01 Stockholm, Sweden. In the last two decades it has become apparent that There is increasing evidence that organic radicals as toxic manifestations of many chemicals arise from well as oxygen radicals may cause acute cell injury covalent interactions of either the compounds and also be involved in the initiation and themselves or more commonly their metabolites promotion of tumor formation. In the cell, with tissue macromolecules. Identification of the peroxidase-mediated metabolism of various drugs products of covalent interaction has demonstrated and carcinogens, and one-electron reduction of that the reactive forms are generally electrophilic. many quinones, e.g. menadione, can be a source of The nature of several classes of electrophiles will be generation of both types of radicals.
    [Show full text]